2009•Journal watchRequires access

Darunavir + Raltegravir + Etravirine = High Rate of Treatment Success

Paul E. Sax

Abstract

Can treatment-experienced patients now achieve virologic suppression at rates comparable to those seen in patients new to therapy? The answer — based on this prospective study of darunavir, etravirine, and raltegravir combined — is an emphatic yes. Multiclass treatment–experienced patients from 49 HIV clinics in France were eligible for enrollment if they had never received any of the three agents and …

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Etravirine, Raltegravir, Darunavir, Medicine, Maraviroc, Antiretroviral therapy, Human immunodeficiency virus (HIV), Internal medicine